IJCRR - Vol 08 Issue 11, June, 2016
GENE XPERT BASED ONE YEAR ANALYSIS OF PULMONARY KOCH’S FROM NORTH MAHARASHTRA REGION
Author: Mrudula Dravid, Sukhada Buwa, Shubhangi Dange, Hitesh Adchitre
Introduction: Tuberculosis is a major public health problem in the world, especially in the developing countries like India. Also MDR-TB and HIV: TB co-infection are major hurdles to achieve the aim and objectives of our national tuberculosis programme.
1. To diagnose Mycobacterium tuberculosis (MTB) infection in clinically suspected cases of pulmonary tuberculosis using Gene Xpert.
2. To find out HIV: TB co-infection rate.
3. To find out prevalence of Rifampicin sensitive and resistant cases in diagnosed tuberculosis patients.
4. To study factors responsible for Rifampicin resistance (MDR-TB)
Material and Methods: This retrospective study included 278 sputum samples from Jan 2015-Dec 2015 from registered RNTCP patients. The samples were subjected to Xpert MTB/RIF Assay for use with the Cepheid Gene Xpert. The Ziehl - Neelsen smear finding was provided by the RNTCP –DOTS regional centres.
Results: A total number of 278 sputum samples were subjected to Gene Xpert analysis in the year 2015. MTB could be detected in 137 (49.28%) cases. In the rest 141 cases where MTB was not detected 14 samples reported error on Gene Xpert. Out of 278 cases, 209 (75.18%) were HIV negative, and 69 (24.82%) were HIV positive. In 69 clinically suspected HIV: TB co-infection cases, MTB could be detected in 22 (31.88%) cases. Out of these 22 cases, 4 (18.18%) were smear positive. Out of 137 MTB detected samples, 117 (85.4%) were rifampicin sensitive, 2 (1.46%) were rifampicin indeterminate resistant and 18 (13.14%) were rifampicin resistant. According to RNTCP programme criteria for suspected MDR –TB, out of 18 MDR-TB cases, 12 (66.67%) cases were - smear positive at diagnosis , retreatment case; 3 (16.67%) cases were - any follow up smear positive, 2 (11.11%) - had contact of known MDR -TB case and 1(5.56%) - was HIV: TB case.
Conclusion: Gene Xpert was a useful tool in detection of HIV-TB co-infection. In our study out of 69 clinically suspects HIV: TB co-infection cases, one third cases were confirmed by Gene Xpert. Thus, 44 patients were not put on unnecessary AKT and were kept on follow-up. Even though the association of MDR-TB and HIV co-infection was not very significant in this study, it would not be too long before witnessing a rapid increase of MDR-TB among HIV patients if adequate and immediate measures are not taken. In the present study, MDR-TB detection rate was high among re-treatment cases. Emphasis has to be given for completion of primary treatment on time and taking proper nutrition. Patients usually stop treatment once they feel better within 2 month of starting the treatment. Special counselling and education is needed at this juncture. In our study, two cases of primary MDR-TB were from household contact. Hence, health workers must generate awareness and educate patients and family members about the risk of acquiring Primary MDR-TB to prevent its spread.
Keywords: Gene Xpert, Pulmonary tuberculosis, MDR-TB, HIV: TB co-infection
Mrudula Dravid, Sukhada Buwa, Shubhangi Dange, Hitesh Adchitre. GENE XPERT BASED ONE YEAR ANALYSIS OF PULMONARY KOCH’S FROM NORTH MAHARASHTRA REGION International Journal of Current Research and Review. Vol 08 Issue 11, June, 05-09
1. World Health Organization. Global tuberculosis control: surveillance,planning, financing. WHO report 2008. WHO/ HTM/TB/2008.393. Geneva, Switzerland: WHO, 2008. www. who.int/tb/publications/global_report/2008/en/index.html Accessed June 2009
2. Paramasivan CN. An overview of drug resistant tuberculosis in India. Indian J Tuberc 1998;45:73-81.
3. World Health Organization Report: Global Tuberculosis Control.Surveillance, planning and financing. Geneva, World Health Organization (WHO/HTM/TB/2005.349); 2005.
4. World Health Organization Report: Global Tuberculosis Control.Surveillance, planning and financing. Geneva, World Health Organization (WHO/HTM/TB/2006.362); 2006.
5. World Health Organization Report: Global Tuberculosis Control.Surveillance, planning and financing. Geneva, World Health Organization (WHO/HTM/TB/2007.376); 2007.
6. World Health Organization Report: Global Tuberculosis Control.Surveillance, planning and financing. Geneva, World Health Organization (WHO/HTM/TB/2008.393); 2008.
7. Santha T, Gopi PG, Rajeswari R, Selvakumar N, Subramani R, Chandrasekaran V, Rani B, Thomas A, Narayanan PR: Is it worth treating Category I failure patients with Category I regimen? Ind JTuberc 2005, 52:203-206.
8. Ormerod L.P. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. British Medical Bulletin 2005;73 and 74:17–24.
9. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359:2059–64.
10. Cepheid®. Xpert® MTB/RIF Package Insert Ref GXMTB/RIFUS-10. 2015;(Feb).
11. Region SA. Tuberculosis Control in South-East Asia Region. 2015. 435 p.
12. World Health Organization Report: Global Tuberculosis Control.Surveillance, planning and financing. Geneva, World Health Organization (WHO/HTM/TB/2010.7); 2010.
13. Jaiswal RK, Srivastav S, Mahajan H. Socio demographic profile of TB-HIV co-infected patients in Bundelkhand Region, UttarPradesh. Nat J Med Res. 2012;2:149–51.
14. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009–21.
15. Lawn S, Churchyard G. Epidemiology of HIV associated tuberculosis. Curr Opin HIV AIDS.2009;4:325–33.
16. Geneva (Switzerland): Global tuberculosis control: Epidemiology, strategy, financing; 2009. World Health Organization World Health Organization; p. 411. WHO/HTM/TB/2009.
17. Narain JP, Lo YR. Epidemiology of HIV-TB in Asia. Indian J Med Res. 2004;120:277–89.
18. Sethi S, Mewara A, Dhatwalia SK, Singh H, Yadav R, Singh K, et al. Prevalence of multidrugresistance in Mycobacterium tuberculosis isolates from HIV seropositive and seronegative patients with pulmonary tuberculosis in north India. BMC Infect Dis . BioMed Central; 2013 Jan 15 ;13(1):137.
19. Ghiya R, Naik E, Casanas B, Izurieta R, Marfatia Y. Clinico-epidemiological profile of HIV/TB coinfected patients in Vadodara, Gujarat. Indian J Sex Transm Dis . 2009 Jan;30(1):10–5.
20. Noeske J, Dopico E, Torrea G, Wang H, Van Deun A. Two vs. three sputum samples for microscopic detection of tuberculosis in a high HIV prevalence population. Int J Tuberc Lung Dis. 2009;13:842–7.
21. Magana-Arachchi DN. Tuberculosis - Current Issues in Diagnosis and Management [Internet]. Mahboub B, editor. InTech; 2013 [cited 2016 Mar 30]. Available from: http://www. intechopen.com/books/tuberculosis-current-issues-in-diagnosis-and-management/epidemiology-of-multidrug-resistant-tuberculosis-mdr-tb22. WHO 2015. World Health Organization: MDR-TB 2015 Factsheet Source. Available from: http:// www.who.int/tb/challenges/mdr/mdr_tb_factsheet.pdf.
23. MDRTB_Indicators_map [Internet]. [cited 2016 Mar 30]. Available from: https://extranet.who.int/sree/Reports?op=vsandpath=/ WHO_HQ_Reports/G2/PROD/EXT/MDRTB_Indicators_map 24. WHO.Global Tuberculosis Control:WHO Report 2010.2010[Sept18,2011] Available from: http://www.who.int/ tb/publication/global report/2010/en/index.html 25. BrudneyK,Dobkin J. Resurgent tuberculosis in New York City. HIV virus, homeleness and the decline of tuberculosis control programme. Am Rev Respir Dis 1991;144:748-9. 26. Angarno G, Carbonara S,Costd GoriA. Drug resistant TB in HIV infected persons in Italy.Int J Tuberc Lung Dis 1998;2:301- 11. 27 Maranetra KN. Treatment of multidrug-resistant tuberculosis in Thailand. Chemotherapy1996;42:(Suppl 3):10-15. 28. Chiang C-Y, Centis R, Migliori GB. Drug-resistant tuberculosis: past, present, future. Respirology. 2010;15(3):413–32.